The deal brings Hims & Hers to Germany, France and Ireland, accelerating its international push and expanding digital care across mental health, weight loss and more
Hims & Hers Health Inc. is set to acquire Zava, a European digital health platform with more than a million active users, in an all-cash deal.
The acquisition, expected to close in the second half of 2025, will mark the U.S.-based telehealth company’s official entry into Germany, France and Ireland while expanding its presence in the U.K. The deal will enable Hims & Hers to offer personalized care across dermatology, weight loss, mental health and sexual health.
The telehealth company plans to roll out its branded services in the coming quarters, with additional markets expected, the company said.
“The demand for simpler, more personalized healthcare is universal,” said Hims & Hers founder and CEO Andrew Dudum. “By leveraging Zava’s established European presence, cutting-edge technology and deep customer understanding, we’re poised to fundamentally transform access to care for millions across Europe. Whether in rural towns, vibrant cities or remote communities, people battling widespread, often silent chronic conditions like obesity and depression will have access to the personalized, high-quality care they deserve.”
Hims & Hers said it expects the acquisition to become accretive by 2026.
“Wherever you live, the need is the same: healthcare that’s personal, trustworthy and fast,” said Zava co-founder and CEO David Meinertz. “By joining forces with Hims & Hers, we can put that standard within reach of millions more people across Europe. Together, we’ll pair Zava’s trusted clinical services, established footprint and deep understanding of the European healthcare landscape with the Hims & Hers experience to make affordable access to high-quality, personalized care the rule, not the exception. I’m thrilled to be working with Andrew and his team. It’s still day one for digital healthcare, and I can’t wait to see what we’ll achieve for patients in the years ahead.”
Hims & Hers has recently struck a long-term partnership with pharmaceutical giant Novo Nordisk to offer its weight loss drug, Wegovy, alongside the telehealth platform’s 24/7 virtual care, clinical support and nutrition coaching.
Elsewhere on the domestic front, Hims & Hers acquired Trybe Labs, a New Jersey-based at-home lab testing facility, to support planned offerings in low testosterone treatment and menopausal care. It followed that with the purchase of a California-based peptide facility, aimed at advancing its personalized treatment capabilities.
